Anal cancer
Bavencio for first-line maintenance treatment of locally advanced or metastatic urothelial carcinoma, approved by European Commission
The European Commission ( EC ) has approved Bavencio ( Avelumab ) as monotherapy for the first-line maintenance treatment of...
Co-primary endpoint results from post-marketing required safety study of Xeljanz in patients with rheumatoid arthritis
The co-primary endpoint results from a recently completed post-marketing required safety study, ORAL Surveillance were presented. The primary objective of...
Keytruda as first-line treatment in adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer, approved by European Commission
The European Commission has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, as a monotherapy for the first-line treatment of...
Sotorasib has shown rapid, deep and durable responses in previously treated patients with advanced non-small cell lung cancer with KRAS G12C mutation
Results from the phase 2 cohort of the CodeBreaK 100 clinical study evaluating investigational Sotorasib ( AMG 510 ) in...
Apalutamide has significantly improved overall survival in patients with metastatic hormone-sensitive prostate cancer
The results from the final analysis of the phase 3 TITAN study, which has demonstrated the continued statistically significant benefit...
Osimertinib extendes disease-free survival regardless of prior adjuvant chemotherapy in early-stage EGFR-mutated non-small cell lung cancer
Results from an exploratory analysis of the ADAURA phase III trial have shown Osimertinib ( Tagrisso ) has extended disease-free...
Libtayo as monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of 50% or more, FDA has approved
The FDA ( U.S. Food and Drug Administration ) has approved the PD-1 inhibitor Libtayo ( Cemiplimab-rwlc; Cemiplimab ) for...
Mobocertinib in patients with EGFR exon20 insertion+ metastatic non-small cell lung cancer who received prior Platinum-based chemotherapy
New data from the phase 1/2 trial of Mobocertinib orally administered in previously treated patients with epidermal growth factor receptor...
FDA has expanded approval of Lorbrena as first-line treatment for ALK-positive metastatic non-small cell lung cancer
The FDA ( U.S. Food and Drug Administration ) has approved supplemental New Drug Application ( sNDA ) for Lorbrena...
CLASSICAL-Lung phase 1b/2 clinical trial in non-small cell lung cancer: Pepinemab, a SEMA4D inhibitor, associated with Avelumab, an immune checkpoint inhibitor
Results from CLASSICAL-Lung clinical trial were published in Clinical Cancer Research, a publication of the American Association for Cancer Research...
European Commission: Tecentriq approved as a first-line monotherapy treatment for people with metastatic non-small cell lung cancer whose tumours have high PD-L1 expression, with no EGFR or ALK genomic tumour aberrations
European Commission has approved Tecentriq ( Atezolizumab ) as a first-line treatment for adults with metastatic non-small cell lung...
Tagrisso approved in the EU for the adjuvant treatment of patients with early-stage EGFR-mutated non-small cell lung cancer
Tagrisso ( Osimertinib ), an irreversible epidermal growth factor receptor tyrosine kinase inhibitor ( EGFR TKI ), has been approved...
Adjuvant Nivolumab in resected esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: expanded efficacy and safety analyses from CheckMate 577
In CheckMate 577, Nivolumab ( Opdivo ) has demonstrated a significant and clinically meaningful improvement in disease-free survival ( DFS;...
Dalpiciclib versus placebo plus Fulvestrant in HR+/HER2- advanced breast cancer that relapsed or progressed on previous endocrine therapy
Dalpiciclib, a novel CDK4/6 inhibitor, as monotherapy has demonstrated tolerability and preliminary antitumor activity in pretreated HR+/HER2− advanced breast cancer...
Abecma, the first anti-BCMA CAR T cell therapy for relapsed and refractory multiple myeloma - Approved in European Union
The European Commission ( EC ) has granted Conditional Marketing Authorization for Abecma ( Idecabtagene vicleucel; Ide-cel ), a first-in-class...
Opdivo for the adjuvant treatment of patients with high-risk urothelial carcinoma - Approved by FDA
The U.S. Food and Drug Administration ( FDA ) ha approved Opdivo ( Nivolumab ) 240 mg every two weeks...
Efficacy and safety of Pembrolizumab plus chemotherapy to Pembrolizumab monotherapy: a consecutive analysis of NSCLC patients with high PD-L1 expression
There has been an only indirect comparison between Pembrolizumab ( Keytruda ) and Pembrolizumab plus chemotherapy in patients with non-small...
Apalutamide vs placebo in patients with non-metastatic castration-resistant prostate cancer receiving androgen deprivation therapy: health-related quality of life at final analysis of the SPARTAN study
The phase III SPARTAN study evaluated Apalutamide ( Erleada ) vs Placebo in patients with non-metastatic castration-resistant prostate cancer (...
Capmatinib in patients with METex14-mutated advanced non-small cell lung cancer who received prior immunotherapy: GEOMETRY mono-1 study
MET exon 14 skipping mutations ( METex14 ) are seen in 3-4% of patients with non-small cell lung cancer (...
Advanced urothelial carcinoma: Ibrutinib in combination with Paclitaxel has activity - Final analysis of a phase Ib/II study
Ibrutinib ( Imbruvica ), a once-daily Bruton’s tyrosine kinase ( BTK ) inhibitor approved for various B-cell malignancies, also inhibits...